Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute (NASDAQ: RZLT) has announced the pricing of an underwritten offering of common stock and pre-funded warrants, expected to raise approximately $90 million in gross proceeds. The offering includes 20,786,923 shares of common stock priced at $3.25 per share and pre-funded warrants for up to 6,905,385 shares at $3.2490 per warrant.
The offering features participation from notable investors including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Great Point Partners. Guggenheim Securities is serving as the sole book-running manager. The closing is expected around April 24, 2025. The company plans to use the proceeds for research and development, general corporate expenses, and working capital needs.
Rezolute (NASDAQ: RZLT) received a positive recommendation from the Independent Data Monitoring Committee (DMC) for its Phase 3 sunRIZE study of ersodetug in Congenital Hyperinsulinism (HI). The DMC advised continuing the trial as planned without increasing the sample size.
The interim analysis was conducted after approximately half of enrolled patients completed primary assessments, focusing on hypoglycemia events as the primary endpoint. The company remains on track to complete enrollment in May 2025, with topline data expected in December 2025.
U.S. clinical sites are now active and enrolling patients as part of the global study. The company remains blinded to the partial study data and statistical outputs from the DMC. The recommendation aligns with previous Phase 2 RIZE study outcomes, real-world observations from their Expanded Access Program, and pharmacokinetic data from the sunRIZE study's open-label arm.
Rezolute (Nasdaq: RZLT) has appointed Erik Harris to its Board of Directors, effective immediately. Harris, currently serving as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings over 20 years of biopharmaceutical expertise to the company.
Harris has significant experience in global product launches, building commercial teams, and developing strategic partnerships. His appointment comes at a important time as Rezolute advances its lead programs through clinical development and prepares for potential commercialization, particularly focusing on ersodetug for hyperinsulinism treatment.
Rezolute (NASDAQ: RZLT) reported Q2 FY2025 financial results and business updates. The company's lead drug ersodetug received Breakthrough Therapy Designation and Orphan Drug Designation for hyperinsulinism (HI) treatment. A Data Monitoring Committee reviewed the open-label arm of the sunRIZE study, confirming safe drug concentrations in infant participants.
Financial highlights: Cash position at $105.3 million as of December 31, 2024, down from $127.1 million in June 2024. Q2 R&D expenses increased to $12.6 million from $12.0 million year-over-year. G&A expenses rose to $4.5 million from $3.2 million. Net loss widened to $15.7 million from $13.9 million.
Key milestones: Phase 3 sunRIZE study enrollment expected to conclude in Q2 2025, with topline results in Q4 2025. A Phase 3 study for tumor HI is planned to begin in H1 2025, with results expected in H2 2026.
Rezolute (NASDAQ: RZLT) announced key updates for its Phase 3 sunRIZE study of ersodetug, treating hypoglycemia due to congenital hyperinsulinism. The Data Monitoring Committee (DMC) reviewed the open-label arm involving 8 infant participants aged 3 months to 1 year, confirming that target drug concentrations were safely achieved at tested doses of 5 or 10 mg/kg.
Key findings show ersodetug was generally safe and well-tolerated in infants, with drug levels comparable to effective exposures in older pediatric participants from the Phase 2b RIZE study. The DMC approved infant enrollment in the double-blind portion of the study.
Study enrollment completion is expected in Q2 2025, with topline results in Q4 2025, subject to an upcoming interim analysis. The interim analysis, scheduled for early Q2 2025, could recommend continuing the study as planned, increasing the sample size by 33%, or stopping for futility. If expanded, enrollment would extend to Q4 2025 with results by mid-2026.
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, has announced its participation in the Guggenheim SMID Cap Biotech Conference. The conference is scheduled for February 5-6, 2025, in New York City.
The company's management team will be available for one-on-one meetings with investors throughout the conference. Interested investors can arrange meetings through their Guggenheim representatives.
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company, announced that the FDA granted Breakthrough Therapy Designation to ersodetug (RZ358) for treating hypoglycemia due to congenital hyperinsulinism (HI). This designation, aimed at expediting the development of treatments for serious conditions, is based on Phase 2b (RIZE) study results showing significant hypoglycemia improvement of 75% or better without clinically significant hyperglycemia.
CEO Nevan Charles Elam highlighted 2024 as a transformative year with key clinical milestones. The company plans to finish recruitment for the sunRIZE study and announce topline results in the second half of the year. Additionally, Phase 3 study for tumor HI is set to commence.
Key highlights from 2024:
- FDA lifted partial clinical holds on the Phase 3 sunRIZE study, enabling U.S. site inclusion.
- Received Innovation Passport Designation from the U.K. for congenital HI treatment.
- Preclinical validation for treating hypoglycemia due to non-islet cell tumors (NICTs).
- FDA clearance for a Phase 3 study for tumor HI, with topline results expected in 2026.
- Received Orphan Drug Designation for tumor HI.
- Raised $73 million in June to support clinical programs and operational goals into Q2 2026.
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on rare disease therapies, announced the approval of an inducement award of 150,000 shares of common stock to its new Senior Vice President of Global Product Supply. The award, granted under Nasdaq Rule 5635(c)(4) on November 30, 2024, was priced at the company's closing price on November 29, 2024. The shares will vest 25% after one year of employment, followed by monthly vesting over the subsequent 36 months.
Rezolute (Nasdaq: RZLT) announced that the FDA has granted Orphan Drug Designation to ersodetug for treating hypoglycemia due to tumor hyperinsulinism (HI). The company plans to initiate a Phase 3 registrational trial for ersodetug in tumor HI patients in 2025. The FDA's designation offers seven years of market exclusivity and potential expedited approval pathways. Ersodetug aims to provide a universal treatment for hypoglycemia caused by all forms of HI, addressing a serious unmet medical need and enabling patients to continue cancer treatments while managing hypoglycemia.
Rezolute reported Q1 fiscal 2025 financial results and provided updates on its ersodetug clinical trials for hyperinsulinism (HI). The company is advancing two Phase 3 trials: the sunRIZE study for congenital HI, with U.S. enrollment starting in early 2025, and a tumor HI study commencing in H1 2025. Financial highlights include cash position of $117.8 million as of September 30, 2024, R&D expenses of $12.8 million, and a net loss of $15.4 million. Topline results are expected in H2 2025 for sunRIZE and H2 2026 for the tumor HI study.